What Covalence Research Ltd does

Covalence Research Ltd is a privately held UK-based health economics and evidence synthesis consultancy, headquartered in Harpenden, England (company number 9358078). Founded in 2014, the firm provides specialized services to pharmaceutical and biotechnology companies developing health technologies that require evidence-based submissions to health technology assessment (HTA) bodies. Its service portfolio comprises health economic modeling and analysis (cost-utility models such as the DEVOTE and PRIME Type 2 Diabetes models), systematic literature reviews, network meta-analyses following ISPOR and NICE best-practice guidelines, medical writing and value communications, and data and dashboard development. The company reports successful submissions to NICE (UK), SMC (Scotland), Canada's Drug Agency (CDA-AMC, formerly CADTH), and AMCP (USA), with demonstrable therapy area depth across diabetes, oncology, virology, cardiovascular, autoimmune, dermatology, infectious diseases, and rare diseases.

The firm's delivery is anchored by proprietary technology assets, most notably Sourcerer — an in-house, custom-built platform for rapid systematic literature screening, operated as a sub-brand at sourcerer.pro — and the Secondary Care Medicines Data (SCMD) Dashboard, an off-the-shelf analytical product built on Shiny and Angular. Covalence also sponsors the BUGSnet Bayesian network meta-analysis project in collaboration with the University of Waterloo, stewarding open-source methodology aligned to ISPOR and NICE standards. The team of 12 professionals includes Director Richard Pollock (Cambridge, over 18 years as a health economist, 100+ peer-reviewed publications) and senior staff drawn from Oxford, Imperial College London, LSHTM, Sheffield, King's College London, and Bristol, with senior-level recruits in 2024-2026 sourced from HEOR Ltd, Lumanity (formerly BresMed), and Clarivate.

Covalence operates a professional services, sales-led go-to-market model with project-based, quote-driven engagements rather than published pricing. Distribution is direct-to-enterprise through consulting relationships with pharma and biotech clients across the UK, EU, North America, and APAC. The company is privately held with no disclosed funding rounds, no parent entity, and no public revenue. Revenue mechanics combine fee-for-service consulting with emerging productized revenue from the SCMD Dashboard and Sourcerer platform.

Name

Covalence Research Ltd

Legal name

Covalence Research Ltd

Website

https://covalence-research.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Covalence Research Ltd is a UK-based health economics consultancy that delivers cost-utility modeling, systematic literature reviews, network meta-analyses, medical writing, and data dashboards to pharmaceutical and biotechnology clients preparing submissions to NICE, SMC, CDA-AMC, and AMCP.

Ownership category

akta.pro rank

Product category

Health Economics and Outcomes Research (HEOR) Consulting

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC)

akta.pro secondary industry

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)

Keywords

• Health economics consulting
• Systematic literature reviews
• Medical writing services
• Meta-analysis services
• Health technology assessment

Headquarters

HQ city

Harpenden

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Health Economics Consulting Services: Professional consulting services including health economic modeling, cost-utility analyses, and reimbursement submissions to regulatory bodies (NICE, SMC, CADTH/CDA-AMC). Revenue generated through project-based engagements with pharmaceutical and biotech clients.
2. Evidence Synthesis Services: Systematic literature reviews, meta-analyses, and network meta-analyses conducted as professional service engagements. Forms the basis of peer-reviewed publications and reimbursement submissions.
3. Medical Writing Services: Medical writing and value communications including systematic literature reviews, global value dossiers, value messages, landscape reviews, manuscripts, posters, slide kits and medical education resources.
4. Data and Dashboard Products: Off-the-shelf offerings such as the Secondary Care Medicines Data (SCMD) Dashboard and bespoke dashboards for clients' own datasets using Shiny and Angular technologies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Covalence Research is a health economics and outcomes research (HEOR) consultancy that delivers health economic modelling, systematic literature reviews, meta-analyses, medical writing, and bespoke data dashboards for pharmaceutical and biotechnology clients. Their models and evidence syntheses have formed the basis of successful reimbursement submissions to NICE (UK), SMC (Scotland), CDA-AMC (Canada), and AMCP (USA). They also market the proprietary Sourcerer literature-review platform and an off-the-shelf Secondary Care Medicines Data (SCMD) Dashboard.

Product overview

Covalence Research Ltd is a health economics consultancy offering a portfolio of specialized services and proprietary tools. The core offerings include Health Economic Modeling and Analysis (featuring the DEVOTE Type 2 Diabetes cost-utility model), Systematic Literature Review (powered by their Sourcerer platform), Meta-analysis, Medical Writing, and Data and Dashboard Development. Their off-the-shelf product includes the Secondary Care Medicines Data (SCMD) Dashboard. The company sponsors the BUGSnet project for Bayesian network meta-analysis in collaboration with the University of Waterloo, and operates the Covalence Cloud platform for hosting deliverables.

Differentiator

Problem solved

Functional benefit

Brands

• Sourcerer: Covalence's in-house, custom-built platform for conducting systematic literature reviews.
• Secondary Care Medicines Data (SCMD) Dashboard

Products and services

• Health Economic Modeling and Analysis

Quantifiable outcome

• Over 100 peer-reviewed publications authored by the team
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• University of WaterloocoreStrategic or Co-development PartnerCovalence sponsors the BUGSnet project and works in close collaboration with the University of Waterloo to steward its ongoing development. BUGSnet is software for conducting network meta-analyses following best practice guidelines from ISPOR and NICE.
• Zurich University of Applied Sciences (Switzerland)minorStrategic or Co-development PartnerJohannes Pöhlmann worked on health economic evaluations including for biosimilar infliximab in Switzerland at the Zurich University of Applied Sciences.
• University of Mainz (Germany)minorStrategic or Co-development PartnerJohannes Pöhlmann conducted research on autonomic dysfunction in heart failure at the University of Mainz (Germany).
• World Cancer Research Fund InternationalminorStrategic or Co-development PartnerNeesha Nanu worked as a Research Assistant at Imperial College London on a continuously-updated systematic literature review funded by the World Cancer Research Fund International on the role of diet, nutritional status, anthropometric characteristics and physical activity in cancer prevention and prognosis.
• NICE (National Institute for Health and Care Excellence)coreStrategic or Co-development PartnerSilvia Rabar worked for 9 years in NICE Clinical Guideline development. The company has consistently delivered models that have resulted in successful reimbursement submissions to NICE.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Parexel International: Global CRO with HEOR and market access services supporting HTA submissions. Provides end-to-end drug development services that compete for the same pharma client wallet as Covalence's specialized offering.
• ICON plc: Global CRO with health economics, market access, and HTA submission capabilities. Larger and broader portfolio than Covalence but overlaps on cost-effectiveness modeling and reimbursement support for pharma clients.
• Syneos Health: Global biopharma services organization offering commercial, clinical, and HEOR consulting. Competes for pharma market access and evidence generation engagements at much larger scale than Covalence.
• Clarivate: Global information services and consulting firm with significant real-world evidence, market access, and HEOR offerings. Overlaps Covalence on medical writing and value communications; Covalence's Martin Field joined from Clarivate.
• IQVIA: Largest global CRO with a substantial HEOR and real-world evidence practice. Competes for the same pharma HEOR budget as Covalence but offers integrated clinical, commercial, and real-world evidence services at much greater scale.

Direct peers

• RTI Health Solutions: Dedicated HEOR research organization within RTI International, providing health economics, systematic review, and HTA submission services globally. Closely aligned to Covalence on evidence synthesis, cost-utility modeling, and value dossier production for pharma/biotech.
• Cytel: Specialist in biostatistics and HEOR providing evidence generation, meta-analysis, and health economics services to pharma/biotech. Directly comparable on the evidence synthesis and statistical methodology side of Covalence's offering.
• Lumanity (formerly BresMed): Global HEOR and market access consultancy with deep HTA submission expertise across NICE, SMC, and other agencies. Directly competes in the same value dossier, evidence generation, and health economic modeling space; Covalence's Rose Hart previously led R-modelling at Lumanity/BresMed.
• HEOR Ltd: UK-based health economics and outcomes research consultancy. Directly comparable as a boutique HEOR firm serving pharma/biotech clients with HTA submission support; notably, two of Covalence's recent senior hires (Tray Brown, Matt Tucker) joined from HEOR Ltd.
• Maverix Information Services: Boutique HEOR and market access consultancy serving pharma with health economic modeling, evidence synthesis, and HTA submission support. Comparable scale and service mix to Covalence, with overlap in NICE/SMC/CADTH submission work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/_covalence

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Covalence Research Ltd